Sign up for a free trial now
  • Login
  • Subscribe
  • Take a FREE Trial
  • About Us
  • Contact us
  • RSS

26 May 2013


The Pharma Letter
  • Home
  • 7 Day Premium Trial
  • Pharmaceuticals
  • Biotechnology
  • Generics
  • Events
  • Companies
  • Drugs
  • Subscribe

Centocor Ortho Biotech Articles

AVEO Pharma licenses RON-targeted antibodies to Johnson & Johnson unit for up to $555 million

1 June 2011

Johnson & Johnson unit voluntarily withdraws NDA for trabectedin

3 May 2011

Abbott prevails as US Court of Appeals overturns $1.8 billion patent verdict for J&J unit

24 February 2011

Johnson & Johnson unit seeks US FDA label expansion for RA drug Simponi

12 November 2010

Abbott/Eisai's Humira emerges as market leader in psoriatic arthritis, garnering sales of over $500 million in 2009

5 November 2010

Rheumatoid arthritis patient share of Actemra projected to exceed that of Cimzia and Simponi among US Medicare population

4 November 2010

J&J unit Centocor Ortho buys RespiVert; VaxGen to acquire diaDexus in stock merger

1 June 2010

Changes brewing in the US renal anemia market, suggest reports from BioTrends

28 April 2010

Showing 1-8 of 8 articles

Go to beginningPrevious
  • 1
NextGo to end
  • Hot Topics
  • Most Read
  • Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
  • Proposal to list Roche's Neulastim and Actemra in New Zealand
  • Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
  • Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
  • Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
  • Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
  • Proposal to list Roche's Neulastim and Actemra in New Zealand
  • Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
  • Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
  • Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth

30 Day Premium Trial


Events

Twitter Right banner

RSS



© 2013 thepharmaletter.com

  • Home
  • RSS
  • About Us
  • Subscribe
  • Terms and Conditions
  • Article Archive
Site powered by WORKSsitebuilder CMS